PCK2 antibody
GTX114919
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetPCK2
Overview
- SupplierGeneTex
- Product NamePCK2 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- FormulationLiquid
- Gene ID5106
- Target namePCK2
- Target descriptionphosphoenolpyruvate carboxykinase 2, mitochondrial
- Target synonymsepididymis secretory sperm binding protein; PEP carboxykinase; PEPCK; PEPCK2; PEPCK-M; phosphoenolpyruvate carboxykinase [GTP], mitochondrial; phosphopyruvate carboxylase
- HostRabbit
- IsotypeIgG
- Protein IDQ16822
- Protein NamePhosphoenolpyruvate carboxykinase [GTP], mitochondrial
- Scientific DescriptionThis gene encodes a member of the phosphoenolpyruvate carboxykinase (GTP) family. The protein is a mitochondrial enzyme that catalyzes the conversion of oxaloacetate to phosphoenolpyruvate in the presence of GTP. A cytosolic form encoded by a different gene has also been characterized and is the key enzyme of gluconeogenesis in the liver. The encoded protein may serve a similar function, although it is constitutively expressed and not modulated by hormones such as glucagon and insulin that regulate the cytosolic form. Alternatively spliced transcript variants have been described. [provided by RefSeq]
- ReactivityHuman, Mouse, Rat
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. Chu PY et al., 2017 Nov 28, OncotargetRead more